Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

136.87 -1.31 (-0.95%)
Streaming Delayed Price Updated: 2:15 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 Next >
Earnings Scheduled For April 23, 2024
Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion. 
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:DGX.
Uncovering Dividend Opportunities with QUEST DIAGNOSTICS INC (NYSE:DGX). 
Via Chartmill
Key Takeaways From Quest Diagnostics Analyst Ratings
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. 
Via Talk Markets
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
The Analyst Landscape: 5 Takes On Quest Diagnostics
Via Benzinga
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth. 
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX). 
Via Chartmill
(DGX) - Analyzing Quest Diagnostics's Short Interest
Via Benzinga
Why NYSE:DGX provides a good dividend, while having solid fundamentals.
Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX). 
Via Chartmill
US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory'
Wall Street appears to be shrugging off rate worries as major stock index futures were moderately higher in early pre-market trading on Monday in the hopes of getting some respite from Big Tech... 
Via Benzinga
AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow
Benzinga used Public.com's bond screener tool to identify some of the highest-yielding investment-grade corporate bonds. 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Breaking Down Quest Diagnostics: 7 Analysts Share Their Views
Via Benzinga
Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Is NYSE:DGX suited for dividend investing?
Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. 
Via Chartmill
Beyond The Numbers: 7 Analysts Discuss Quest Diagnostics Stock
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
Earnings Scheduled For February 1, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... 
Via Benzinga
Earnings Outlook For Quest Diagnostics
Via Benzinga
Investor Sentiment Falls Sharply Following Fed's Rate Decision; Dow Dips Over 300 Points
The CNN Money Fear and Greed index showed a sharp decline in the overall market sentiment, while the index remained in the "Greed" zone on Wednesday. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Quest Diagnostics Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Quest Diagnostics Incorporated (NYSE: DGX) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 1, 2024. 
Via Benzinga
The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market
With the value of the cancer testing market expected to soar over the next decade, here are the three best disease testing stocks to buy now. 
Via InvestorPlace
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection. 
Via Benzinga
Consulting Firm McKinsey Concludes Opioid Litigation Settlement With $78M Agreement
Consulting giant McKinsey & Co, on Friday, agreed to a settlement of $78 million to resolve allegations tied to the opioid epidemic, as disclosed in federal court papers filed in San Francisco.  
Via Benzinga
Expert Ratings for Quest Diagnostics
Via Benzinga
Quest Diagnostics Gains Momentum: Analyst Highlights Strong Business Trends And Growth Opportunities
Truist Securities analyst David S. 
Via Benzinga
Supreme Court Set to Decide Future of Mifepristone: Showdown Looms Over FDA's Endorsement
The U.S. Supreme Court is set to deliberate on the future of mifepristone, a crucial drug employed in over half of all abortions within the U.S.  
Via Benzinga
Exposures Product Safety
Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight
The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.  
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.